Immunosuppressants - G20

The Immunosuppressants market is anticipated to witness a significant surge in revenue, reaching a staggering US$50.71bn by the year 2024.
This growth is expected to continue at a steady pace, with an impressive Compound Annual Growth Rate (CAGR) of 15.02% from 2024 to 2029.
As a result, the market volume is projected to reach a substantial US$102.10bn by the end of 2029.
In the global landscape, it is noteworthy that United States will contribute the most to this market.
The United States is expected to generate an impressive revenue of US$35,470.00m in 2024, solidifying its position as the leading player in the Immunosuppressants market among the G20 countries.
In Germany, there is a growing trend towards the use of biosimilar immunosuppressants to reduce healthcare costs.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The Immunosuppressants market in G20 has been experiencing steady growth in recent years.

Customer preferences: Patients suffering from autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus are the primary customers of immunosuppressants. The increasing prevalence of these diseases, coupled with the growing aging population, has led to a rise in demand for immunosuppressants.

Trends in the market: In the United States, the largest market for immunosuppressants, the market is dominated by biologics. This trend is expected to continue as more biologics are approved for use in the country. In Europe, biosimilars are gaining popularity, and their use is expected to increase in the coming years. In Japan, the market is shifting towards generic immunosuppressants due to the government's efforts to reduce healthcare costs.

Local special circumstances: In China, the market for immunosuppressants is growing rapidly due to the increasing prevalence of autoimmune diseases and the government's efforts to improve healthcare access. In India, the market is largely driven by the availability of affordable generic immunosuppressants. In Brazil, the market is dominated by biologics due to the high cost of these drugs and the government's efforts to increase access to them.

Underlying macroeconomic factors: The increasing prevalence of autoimmune diseases and the growing aging population are the primary macroeconomic factors driving the growth of the immunosuppressants market. Additionally, the increasing focus on research and development by pharmaceutical companies is leading to the development of new and more effective immunosuppressants. The rising healthcare expenditure in many countries is also contributing to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.